The expression of I-FABP in BE treatment groups was observably lower than the HFD group (P<0.001 or P<0.01), and the therapeutic effects of BE at high dosage were better than fenofibrate (P<0.01) (Figure 5B). This evidence concerns the gene FABP2 and Barrett esophagus.